Calculateur du score entier préprocédural Mehran 2, modèle 1

État

clinical-review-pending

Version de la méthode

Mehran 2 (2021) Model 1 pre-procedural integer mapping, source-faithful-2021-model-1: clinical presentation = asymptomatic or stable angina 0, unstable angina 2, NSTEMI 4, STEMI 8; documented CKD-EPI 2009 creatinine eGFR (mL/min/1.73 m²) >=60 is 0, >=30 to <60 is 1, <30 is 4; LVEF <40% is 2; diabetes = none 0, non-insulin-treated 1, insulin-treated 2; hemoglobin <11 g/dL is 1; basal glucose >=150 mg/dL is 1; congestive heart failure on presentation is 1; completed whole age >75 years is 1; raw integer total 0–20 without rounding, imputation, risk category, or event probability

Population

Adults represented by the single-US-tertiary-centre derivation cohort (14,616 index PCI patients treated in 2012–2017) and temporal same-centre validation cohort (5,606 treated in 2018–2020), with chronic dialysis and multiple procedures excluded and all eight Model 1 variables documented before one index PCI. The eGFR must have been calculated outside this tool with the 2009 CKD-EPI creatinine equation. The source creatinine-defined CA-AKI outcome was a serum-creatinine increase of at least 0.3 mg/dL or at least 50% from pre-PCI within 48 hours; urine-output data were unavailable and not used.

Limites et exclusions

Post-procedural Mehran 2 Model 2, contrast-volume or cath-lab procedural components, repeated or staged procedures, multiple-procedure episodes, chronic dialysis, or a missing or incomplete pre-procedural assessment. · A 2021 CKD-EPI or other eGFR equation, calculator-derived or race-solicited eGFR, inferred or imputed values, default-normal categories, or rounding across a source boundary. · Diagnostic angiography without PCI, CT contrast, peripheral intervention, TAVR or another structural procedure, pediatric use, or automatic transfer to a different population, procedure, endpoint, or institution. · Risk group, event probability or rate, locally calibrated prediction, CA-AKI diagnosis, contrast-causal kidney-injury attribution, prognosis, reassurance, prevention recommendation, contrast target, hydration or medication instruction, dialysis decision, disposition, management, or treatment guidance.

• https://doi.org/10.1016/S0140-6736(21)02326-6
• https://ars.els-cdn.com/content/image/1-s2.0-S0140673621023266-mmc1.pdf
• https://doi.org/10.1016/j.jcin.2023.06.015
• https://pubmed.ncbi.nlm.nih.gov/19414839/
• https://pubs.rsna.org/doi/10.1148/radiol.2019192094

Outil importé de la bibliothèque PharmaTek de MDose. Aucune date de révision clinique indépendante n’est documentée dans cette version.

Bibliothèque source

PharmaTek · MDose

Version importée

4b66536936ed

État de publication

Révision clinique en cours